By Mill Chart
Last update: Mar 27, 2025
For growth-minded investors, high revenue and EPS growth are key criteria. Today, we'll examine whether HALOZYME THERAPEUTICS INC (NASDAQ:HALO) fits the bill for growth investing, particularly as it forms a base and hints at a potential breakout. Remember, due diligence is essential, but HALOZYME THERAPEUTICS INC has caught our attention on our screen for growth with base formation. It may warrant additional investigation.
ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of HALO, the assigned 8 reflects its growth potential:
ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. HALO scores a 8 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, HALO has achieved a 8:
The Setup Rating of a stock determines to which extend the stock is consolidating. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. For HALO this score is currently 8:
HALO has an excellent technical rating and also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. A pullback is taking place, which may present a nice opportunity for an entry. There is a resistance zone just above the current price starting at 64.42. Right above this resistance zone may be a good entry point. There is a support zone below the current price at 63.81, a Stop Loss order could be placed below this zone. Very recently a Pocket Pivot signal was observed. This is another positive sign.
Our Strong Growth screener lists more Strong Growth stocks and is updated daily.
Check the latest full fundamental report of HALO for a complete fundamental analysis.
Check the latest full technical report of HALO for a complete technical analysis.
This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
53.295
+1.27 (+2.45%)
Find more stocks in the Stock Screener
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth opportunities.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
HALOZYME THERAPEUTICS (NASDAQ:HALO) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a compelling pick for value investors.